Christian Angermayer is a serial entrepreneur, investor, and founder of his private investment firm, Apeiron Investment Group (www.apeiron-investments.com). With more than USD 3.5 billion under management and 50 FTEs across five international locations, Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech/Crypto, and FutureTech (e.g. SpaceTech, FoodTech, AI). Apeiron has a global approach and deploys its capital across the entire company lifecycle, from founding companies inhouse, seed/startup investments to large-scale investments in listed companies. As Apeiron invests predominantly its own capital, the team is able to be highly entrepreneurial, reliable and flexible. A key company within the Apeiron portfolio is atai Life Sciences (NASDAQ: ATAI), which was founded by Christian in 2018. atai is already making significant headway towards unlocking innovative treatments to improve the status quo for the one billion plus people worldwide suffering from mental health issues, including depression, anxiety, addiction, and post-traumatic stress disorder. atai currently has multiple projects underway to investigate the potential of psychedelic compounds like “magic mushrooms” / psilocybin, DMT (N-Dimethyltryptamine) and Ibogaine, and establish these as approved medical treatments.